Company intelligence / Profile preview
Syntiron
Saint Paul, Minnesota, United Statessyntiron.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Syntiron is developing vaccines targeting bacterial iron receptors. Their lead vaccine targets UTIs, and they received CARB-X funding of US$1.7 million in January 2024 to develop a maternal vaccine against neonatal sepsis.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
CARB-X
Beyond the preview
Go deeper on Syntiron.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syntiron.